AVITA Medical, Inc. (FRA:51KB)

Market Cap	113.70M -50.4%
Revenue (ttm)	61.71M +20.6%
Net Income	-41.38M
EPS	-1.54
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1
Open	0.7440
Previous Close	0.7040
Day's Range	0.7440 - 0.7440
52-Week Range	0.5240 - 1.9600
Beta	n/a
RSI	55.92
Earnings Date	Feb 12, 2026

About AVITA Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Cary Vance
• Employees: 260
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 51KB

Financial Performance

In 2024, AVITA Medical's revenue was $64.25 million, an increase of 28.14% compared to the previous year's $50.14 million. Losses were -$61.85 million, 74.8% more than in 2023.

Financial numbers in USD